- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr John Ward on Conversations With Patients After Multigene Testing
Multigene testing provides a lot of information that providers have to be familiar with in order to adequately explain it to their patients, said John H. Ward, MD, Huntsman Cancer Institute at the University of Utah.
Multigene testing provides a lot of information that providers have to be familiar with in order to adequately explain it to their patients, said John H. Ward, MD, Huntsman Cancer Institute at the University of Utah.
Transcript
How does multigene testing change conversations between patients and providers?
I don’t think it’s changed much, because they’ve been available for a long time. I think there’s a lot of information there, and it requires being familiar with the assays so you can make sense of them to the patient, telling them how they’ve been tested, how to interpret the data. Two of the companies that have recently changed their reports, which make them much more easy to use and explain to patients the benefits or lack of benefits, and I applaud their decision to simplify things.
ALL Disparities, Treatment Gaps: AYA Patients Face Unique Challenges
June 4th 2025Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and unmet needs for effective third-line treatments, highlighting urgent care gaps.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Depth of Responses, PFS in Transplant-Ineligible Patients Match Overall Findings in CEPHEUS
June 2nd 2025Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.
Read More
